Determination of bleeding risk in thrombocytopenic patients with platelet transfusion therapy.
In a clinical study (50 thrombocytopenic patients) we determined the bleeding risk and the platelet transfusion efficacy by a special modification of the in vitro bleeding test (IVBT, Thrombostat 4000). Additionally, cell count, hematocrit, body temperature, platelet volume and distribution width, Simplate bleeding time and a bleeding score were investigated. The use of the modified IVBT proved to be promising to find a clearer indication of platelet transfusion and to estimate its efficacy.
Kretschmer
V
V
Department of Transfusion Medicine and Hemostaseology, University Hospital, Marburg, Germany.
Huss
B
B
Weber
S
S
Bewarder
S
S
Schulzki
T
T
Köppler
H
H
Heimanns
J
J
D001760:Bleeding Time; D001772:Blood Cell Count; D001831:Body Temperature; D006470:Hemorrhage / Q000453:epidemiology*; D006801:Humans; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000628:therapy*; D018570:Risk Assessment